Template:Androgen/anabolic steroid dosages for breast cancer

From blackwiki
< Template:Androgen
Revision as of 06:26, 22 October 2020 by Blackwikiadmin (talk | contribs) (12 revisions imported)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Androgen/anabolic steroid dosages for breast cancer

Route Medication Form Dosage Refs
Oral Template:No selflink Tablet 30–200 mg/day [1][2][3][4]
Template:No selflink Tablet 10–40 mg 3x/day [1][5][6][7]
Template:No selflink Tablet 40–80 mg 4x/day [1][7]
Template:No selflink Tablet 40 mg/day [2]
Buccal Template:No selflink Tablet 25–100 mg/day [4]
Injection (IM or SC) Template:No selflink Oil solution 50–100 mg 3x/week [1][2][8][6][7]
Template:No selflink Oil solution 200–400 mg 1x/2–4 weeks [9][10]
Template:No selflink Oil solution 200–400 mg 1x/2–4 weeks [10][11]
Template:No selflink Oil solution 250 mg 1x/week [6]
Template:No selflink Aqueous suspension 100 mg 3x/week [8][11]
Template:No selflink Aqueous suspension 300 mg 3x/week [2][8][12][11]
Template:No selflink Oil solution 100 mg 1–3x/week [1][2][7]
Template:No selflink Oil solution 400 mg 3x/week [7]
Template:No selflink Oil solution 50–100 mg 1x/1–3 weeks [13][14][15]
Template:No selflink Oil solution 50–100 mg/week [16][7]
Note: Dosages are not necessarily equivalent.
Template documentation

See also

References

  1. 1.0 1.1 1.2 1.3 1.4 Aurel Lupulescu (24 October 1990). "Hormones and Hormonotherapy". Hormones and Vitamins in Cancer Treatment. CRC Press. pp. 33–90. ISBN 978-0-8493-5973-6.
  2. 2.0 2.1 2.2 2.3 2.4 Dao, Thomas L. (1975). "Pharmacology and Clinical Utility of Hormones in Hormone Related Neoplasms". In Alan C. Sartorelli; David G. Johns (eds.). Antineoplastic and Immunosuppressive Agents. pp. 170–192. doi:10.1007/978-3-642-65806-8_11. ISBN 978-3-642-65806-8.
  3. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/083976s031lbl.pdf
  4. 4.0 4.1 Manuchair Ebadi (31 October 2007). Desk Reference of Clinical Pharmacology. CRC Press. pp. 434–. ISBN 978-1-4200-4744-8.
  5. Michael Clinton Perry (2008). The Chemotherapy Source Book. Lippincott Williams & Wilkins. pp. 369–. ISBN 978-0-7817-7328-7.
  6. 6.0 6.1 6.2 G. Martz (13 March 2013). Die hormonale Therapie maligner Tumoren: Endokrine Behandlungsmethoden des metastasierenden Mamma-, Prostata- und Uterus-Corpuscarcinoms. Springer-Verlag. pp. 39–. ISBN 978-3-642-86282-3.
  7. 7.0 7.1 7.2 7.3 7.4 7.5 Janet Brotherton (1976). Sex Hormone Pharmacology. Academic Press. p. 437. ISBN 978-0-12-137250-7.
  8. 8.0 8.1 8.2 Council on Drugs (1960). "Androgens and estrogens in the treatment of disseminated mammary carcinoma: retrospective study of nine hundred forty-four patients". JAMA. 172 (12): 1271–83. doi:10.1001/jama.1960.03020120049010.
  9. https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/009165s031lbl.pdf
  10. 10.0 10.1 American Medical Association. Division of Drugs; American Society for Clinical Pharmacology and Therapeutics (1983). "Androgens and Anabolic Steroids". AMA Drug Evaluations. American Medical Association. pp. 913–930. ISBN 978-0-89970-160-8. TESTOSTERONE CYPIONATE [Andro-Cyp, Depo-Testosterone, T-Ionate-P.A.] TESTOSTERONE ENANTHATE [Andryl, Delatestryl] These long-acting, potent esters of testosterone can maintain the testosterone level within the normal range in males for two to four weeks. [...] For metastatic breast carcinoma in women, 200 to 400 mg every two or more weeks.
  11. 11.0 11.1 11.2 Green RB, Sethi RS, Lindner HH (July 1964). "Treatment of advanced carcinoma of the breast: Progress in therapy during the past decade". Am. J. Surg. 108: 107–21. doi:10.1016/0002-9610(64)90094-7. PMID 14182428.
  12. Segaloff, Albert; Horwitt, Benjamin N.; Cakabasi, Ralph A.; Murison, Path J.; Osser, Joskph V. Scht. (1955). "Hormonal therapy in cancer of the breast.VIII. The effect of dihydrotestosterone (Androstanolone) on clinical course and hormonal excretion". Cancer. 8 (1): 82–86. doi:10.1002/1097-0142(1955)8:1<82::AID-CNCR2820080110>3.0.CO;2-R. ISSN 0008-543X.
  13. https://web.archive.org/web/20190309024812/https://gp2u.com.au/static/pdf/D/DECA-DURABOLIN-PI.pdf
  14. https://web.archive.org/web/20180128030754/http://medsafe.govt.nz/profs/Datasheet/d/Decadurabolininj.pdf
  15. Ronald I. Shorr (11 April 2007). Drugs for the Geriatric Patient E-Book. Elsevier Health Sciences. pp. 844–. ISBN 978-1-4377-1035-9.
  16. W. Llewellyn McKone (11 November 2013). Osteopathic Athletic Health Care: Principles and practice. Springer. pp. 125–. ISBN 978-1-4899-3067-5.